ReviewRegenerative biomaterials2026
Development and translation of biodegradable metal stents: from heart to brain.
Review in Regenerative biomaterials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biodegradable metal stents offer a promising approach for vascular intervention by providing temporary mechanical support and subsequently degrading once healing is complete. While significant progress has been made in cardiovascular applications, their adaptation for cerebrovascular use remains an active area of research. This review systematically examines three key biodegradable metal systems: Fe, Zn and Mg alloys. It traces their development and specific considerations in the transition from cardiac to cerebral indications. Fe-based stents exhibit high mechanical strength but degrade slowly, prompting strategies to accelerate corrosion. Zn-based stents provide a more moderate degradation rate and favorable biocompatibility, yet their neurovascular safety profile requires further assessment. Mg-based stents, which degrade rapidly and may confer neuroprotective benefits, have advanced into clinical use, though controlling their degradation kinetics remains essential. Translating these stents to the delicate and tortuous cerebrovascular environment introduces specific challenges, including the need for enhanced anatomical conformability, mitigation of potential neurotoxicity from degradation byproducts, and reduction of MRI artifacts. Future development will depend on material-specific strategies: accelerating degradation for Fe alloys, refining controlled-release coatings for Zn alloys, and leveraging the neuroprotective potential of Mg alloys. Ultimately, success hinges on optimizing stent degradation and neurovascular compatibility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.